Salt AI, a leading provider of contextual AI solutions for enterprise applications in life sciences and health technology, has announced a $10 million funding round led by Morpheus Ventures, with participation from Struck Capital, Marbruck Investments, and CoreWeave. The investment will enable Salt AI to broaden its footprint among top biopharma and healthcare organizations pioneering advanced AI applications, while expanding its global AI engineering teams to accelerate delivery and impact. The platform is already being adopted across key areas including drug discovery, clinical development, revenue cycle management, intelligent data navigation, and enterprise operations.
“Salt AI is the kind of company CoreWeave aims to support, applying AI to one of society’s most urgent challenges,” said Brian Venturo, Co-founder and Chief Strategy Officer, CoreWeave. “Our AI cloud platform is purpose-built for complex models, enabling Salt Ai to run workloads quickly and reliably and giving life sciences companies a practical way to integrate AI into everyday research.”
Salt AI’s contextual AI platform demystifies the “black box” of enterprise AI applications for pharmaceutical, biotech, and healthcare organizations. Its visual-first interface, combined with full code capabilities, transforms how teams design, deploy, and scale AI-powered workflows throughout the value chain.
Also Read: Pfizer to Acquire Metsera and Its Obesity Pipeline
“We are in the midst of a breakthrough moment in life sciences, with AI igniting unprecedented opportunities that were once out of reach,” said Aber Whitcomb, CEO and Co-Founder of Salt AI. “No single AI model can unlock the future of medicine alone. The future belongs to ensembles, models working in synergy. At Salt AI, our platform is designed so organizations can rapidly create, launch, and scale AI solutions that drive healthcare innovation forward. We’re proud that a growing roster of major enterprises already relies on us to reach new milestones in discovery and improve real-world outcomes across the industry.”
The platform’s impact is already visible at the Ellison Medical Institute (EMI), where Salt AI has been advancing computational biology breakthroughs since summer 2024. EMI leverages the platform to accelerate drug discovery, designing and analyzing thousands of compounds and progressing two promising protein candidates to in-depth wet-lab studies based on positive in vitro results as of August 2025. The platform’s adaptable workflow capabilities allow continuous refinement of EMI’s in silico design approach.
“Salt AI represents a transformative advance in the computational biology stack,” said Dr. David Agus, Founding CEO of the Ellison Medical Institute. “By combining drag‑and‑drop workflows with transparent AI integration, the platform enables a new paradigm of therapeutic design, one that is faster, more efficient, and highly data-driven.”
At the heart of Salt AI’s offering is the Salt Matrix, a comprehensive library of sector-specific data connectors, models, and solutions. It empowers teams to rapidly build AI workflows with intuitive drag-and-drop tools.
Salt AI drives enterprise value through three core pillars:
-
Visual Collaboration: Enables scientists, technologists, and executives to work in real time, bridging the “bilingual talent” gap.
-
Speed to Value: Deployable in private cloud or on-prem environments within days, delivering immediate benefits.
-
Trusted Compliance & Scale: Provides a fully compliant stack that integrates proprietary data, workflows, and models, supporting enterprise-grade adoption.
With this latest funding and growing adoption, Salt AI is poised to redefine AI-driven innovation across life sciences and healthcare enterprises.